​

Clearmind Medicine Stock (NASDAQ:CMND)

FinancialsChart
Clearmind Medicine by TradingView

Previous Close

$1.28

52W Range

$0.92 - $3.58

50D Avg

$1.40

200D Avg

$1.33

Market Cap

$5.04M

Avg Vol (3M)

$264.57K

Beta

-1.51

Div Yield

-

CMND Company Profile

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

4

IPO Date

Nov 15, 2022

Website

CMND Performance

CMND Financial Summary

Oct 23Oct 22Oct 21
Revenue---
Operating Income$-8.50M$-8.53M$-3.45M
Net Income$-11.63M$-9.41M$-4.12M
EBITDA$-8.42M$-8.42M$-3.45M
Basic EPS$-57.42$-217.16$-133.37
Diluted EPS$-57.42$-217.16$-133.37

Fiscal year ends in Oct 23 | Currency in USD

Peer Comparison

TickerCompany
REVBRevelation Biosciences, Inc.
CNSPCNS Pharmaceuticals, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
VRAXVirax Biolabs Group Limited
IMMXImmix Biopharma, Inc.
WINTWindtree Therapeutics, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
UNCYUnicycive Therapeutics, Inc.
CDIOCardio Diagnostics Holdings, Inc.